
Amwill Health Care Limited
Amwill Health Care Limited(AMWILL)
Issue Size
₹54,03,600
Issue Price
₹59.98 Cr
Price Band
₹105 – ₹111
Lot Size
1200 shares
Min. Investment
₹1,26,000
Max. Investment
₹1,33,200
Open Date
05 Feb, 2025
Close Date
07 Feb, 2025
Allotment
10 Feb, 2025
Listing
12 Feb, 2025
Max. Investment
₹1,33,200
Announced
05 Feb, 2025
Opening Date
05 Feb, 2025
Closing Date
07 Feb, 2025
Basis of Allotment
10 Feb, 2025
Initiation of Refunds
11 Feb, 2025
Credit of Shares
11 Feb, 2025
Listing Date
12 Feb, 2025
Apply via UPI in 5 minutes
Choose your broker • Zero commission on IPO
About Amwill Health Care Limited IPO
Incorporated in August 2017, Amwill Health Care Limited is a derma-cosmetic development firm that collaborates with contract manufacturers, distributors, and third-party product development agencies. This collaboration has enhanced the company's manufacturing, packaging, and distribution capabilities.
The product portfolio of the Company is divided into two categories, namely,
- Development of generic dermatological solutions and
- Formulating targeted solutions for d
Amwill Health Care Limited IPO Share Price and Issue Size
Issue Breakdown
Shareholding
Dilution: 28.2% increase in shares
Amwill Health Care Limited IPO Financials Health
Amwill Health Care Limited IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 1200 | ₹1,33,200 |
| Retail Maximum | 1 | 1200 | ₹1,33,200 |
| HNI Minimum | 2 | 2400 | ₹2,66,400 |
(All values in CR)
Amwill Health Care Limited IPO Valuation
| Metric | Value |
|---|---|
| EPS Post IPO | 7.33 |
| EPS Pre IPO | 2.00 |
| P/E Post IPO | 15.13 |
| P/E Pre IPO | 55.6 |
(All values in CR)
Strength & Risk of Amwill Health Care Limited IPO
1. Extensive product portfolio supported by product formulation capabilities and dynamic advisory board of reputed dermatologists.
2. Long standing presence through our Promoters with strong brand equity.
3. Provision of high-quality product development through tie ups with contract manufacturers and prototype developers.
4. Well experienced management team with proven project management and implementation skills.
1. The company has appointed one of its Promoter Group entities, M/s. Amderma Healthcare LLP as a carrying and forwarding agent for storing, delivering and distributing its products. Consequently, the company derives all of its revenue from M/s. Amderma Healthcare LLP. Any non-performance or breach of covenants of the carrying and forwarding agreement executed with M/s. Amderma Healthcare LLP may adversely affect its business operations, profitability and cash flows.
2. The company relies on third party contract manufacturers for manufacturing products of the Company.
3. Its commercial success is largely dependent upon the company's ability to develop and devise problem solving dermacosmetic products. The company has developed a limited number of products since incorporation and therefore, its ability to innovate new products might be limited, which may have an adverse impact on its revenue and profitability.
4. The company derives a significant portion of its revenue from certain of the company products. If sales volume or price of such products declines in the future, or if the company is unable to sell such products for any reason, its business, financial condition, cash flows and results of operations could be adversely affected.
5. Its business and prospects may be adversely affected if the company is unable to maintain and grow the image of its brands. Further, pursuant to the Memorandum of Understanding dated March 31, 2020 executed between M/s. Amwill Healthcare and the Company (Asset Transfer MoU), its Promoter Anand Gandhi has transferred all the trademarks which were previously owned by M/s. Amwill Healthcare. The Company has made applications before the Registrar of Trademarks for registering the Asset Transfer MoU and change in ownership of the aforementioned trademarks, which are presently pending.
6. If the company is unable to anticipate and respond to changes in the market trends and changing customer preferences in a timely and effective manner, or if the company fails to maintain its reputation, brand value or increase the market for its products, the demand for the company products may decline.
7. Its business largely depends on the performance of the company marketing team. Further, the success of its products are dependent upon dermatologists and medical professionals accepting its products and prescribing them to their patients. Any non-performance by our marketing team to market its products before the dermatologists and medical professionals, may adversely affect its business operations, profitability and cash flows.
8. Its operations are concentrated in the states of Karnataka, Andhra Pradesh and Telangana. If revenues from these states decline, its business, results of operations and financial condition would be adversely affected.
9. If the company or M/s. Amderma Healthcare LLP are unable to collect its dues and receivables from end users, its results of operations and cash flows could be adversely affected.
10. Some of its Promoter Group entities may have conflicts of interest as they are engaged in similar industry segment and may compete with it.
Amwill Health Care Limited IPO Subscription Status
| Investor Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (Rs Cr.) |
|---|---|---|---|---|
| HNI | 5.79 | 20,53,200 | 1,18,92,000 | 132 |
| Market Maker | 1.00 | 2,71,200 | 2,71,200 | 3.01 |
| QIB | 7.80 | 10,26,000 | 80,01,600 | 88.82 |
| Retail | 4.77 | 20,53,200 | 97,83,600 | 108.6 |
| Total | 5.78 | 51,32,400 | 2,96,77,200 | 329.42 |
Amwill Health Care Limited IPO GMP
Last updated 31 Jan, 2025 · Source: aggregated grey-market dealers
| Date | IPO Price | GMP | Sub2 Sauda | Est. Listing | Est. Profit | Updated |
|---|---|---|---|---|---|---|
| 31 Jan, 2025 | 111 | ₹0 | -- | ₹111 (0.00%) | - | 31 Jan, 2025 |
| 01 Feb, 2025 | 111 | ₹0 | -- | ₹111 (0.00%) | - | 01 Feb, 2025 |
| 02 Feb, 2025 | 111 | ₹0 | -- | ₹111 (0.00%) | - | 02 Feb, 2025 |
| 03 Feb, 2025 | 111 | ₹0▼ | -- | ₹111 (0.00%) | - | 03 Feb, 2025 |
| 04 Feb, 2025 | 111 | ₹14▲ | 12800 | ₹125 (12.61%) | - | 04 Feb, 2025 |
| 05 Feb, 2025 | 111 | ₹6▲ | 5500 | ₹117 (5.41%) | - | 05 Feb, 2025 |
| 06 Feb, 2025 | 111 | ₹4▲ | 3600 | ₹115 (3.60%) | - | 06 Feb, 2025 |
| 07 Feb, 2025 | 111 | ₹3▲ | 2700 | ₹114 (2.70%) | - | 07 Feb, 2025 |
| 10 Feb, 2025 | 111 | ₹0 | -- | ₹111 (0.00%) | - | 10 Feb, 2025 |
| 11 Feb, 2025 | 111 | ₹0 | -- | ₹111 (0.00%) | - | 11 Feb, 2025 |
| 12 Feb, 2025 | 111 | ₹0 | -- | ₹111 (0.00%) | - | 12 Feb, 2025 |
Disclaimer: GMP is an unofficial signal from grey-market dealers and is not regulated by SEBI. Use it alongside subscription data and other research for informed decision-making.
How to Apply for Amwill Health Care Limited IPO
Login to Your Trading App
Open Zerodha, Upstox, Groww, Angel One, or any brokerage app.
Go to IPO Section
Find Amwill Health Care Limited under the IPO section. Select it and enter your bid details — choose lot size and price (cut-off price recommended).
Enter UPI ID and Submit
Provide your UPI ID linked to your bank account and submit the application.
Approve Mandate on UPI App
Open your UPI app (Google Pay, PhonePe, Paytm, BHIM) and approve the IPO payment request.
Application Confirmed
Your funds will be blocked in your account until the IPO allotment process is completed.